Clinical Trial Update: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating different doses of anti-T lymphocyte globulin (ATLG) for graft-versus-host disease prophylaxis in haploidentical hematopoiet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• ATLG (anti-T lymphocyte globulin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Hematopoietic Stem Cell Transplantation | Phase 3 | Status: NOT_YET_RECRUITING